Today, allogeneic stem cell transplantation (allo-SCT) can be offered to patients up to age 70 to 72 years and represents one of the most effective curative treatments for many hematologic malignancies. The primary objective of the study was to collect data from the allo-SCTs performed in Italy between 2000 and 2017 in patients aged .001). However, after 2012, the HCT-CI score was not significantly predictive of NRM. This study shows that the transplantation procedure in elderly patients became more effective over time. Relapse incidence remains the major problem, and strategies to prevent it are currently under investigation (eg, post-transplantation maintenance). The selection of patients aged 60 could be improved by combining HCT-CI and frailty assessment to better predict NRM. (c) 2021 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
GITMO Registry Study on Allogeneic Transplantation in Patients Aged ≥60 Years from 2000 to 2017: Improvements and Criticisms / M. Malagola, N. Polverelli, V. Rubini, M. Martino, F. Patriarca, B. Bruno, L. Giaccone, G. Grillo, S. Bramanti, P. Bernasconi, M. De Gobbi, A. Natale, E. Terruzzi, A. Olivieri, P. Chiusolo, A.M. Carella, M. Casini, C. Nozzoli, P. Mazza, S. Bassi, F. Onida, A. Vacca, S. Falcioni, M. Luppi, A.P. Iori, V. Pavone, C. Skert, P. Carluccio, C. Borghero, A. Proia, C. Selleri, N. Sacchi, S. Mammoliti, E. Oldani, F. Ciceri, D. Russo, F. Bonifazi. - In: TRANSPLANTATION AND CELLULAR THERAPY. - ISSN 2666-6367. - 28:2(2022 Feb), pp. 96.e1-96.e11. [10.1016/j.jtct.2021.11.006]
GITMO Registry Study on Allogeneic Transplantation in Patients Aged ≥60 Years from 2000 to 2017: Improvements and Criticisms
V. Rubini;F. Onida;N. Sacchi;
2022
Abstract
Today, allogeneic stem cell transplantation (allo-SCT) can be offered to patients up to age 70 to 72 years and represents one of the most effective curative treatments for many hematologic malignancies. The primary objective of the study was to collect data from the allo-SCTs performed in Italy between 2000 and 2017 in patients aged .001). However, after 2012, the HCT-CI score was not significantly predictive of NRM. This study shows that the transplantation procedure in elderly patients became more effective over time. Relapse incidence remains the major problem, and strategies to prevent it are currently under investigation (eg, post-transplantation maintenance). The selection of patients aged 60 could be improved by combining HCT-CI and frailty assessment to better predict NRM. (c) 2021 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
| File | Dimensione | Formato | |
|---|---|---|---|
|
GITMO allo-HCT over 60 years of age - Transp Cell Ther 2022.pdf
accesso aperto
Tipologia:
Publisher's version/PDF
Dimensione
1.95 MB
Formato
Adobe PDF
|
1.95 MB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
